ROSA MARIA FONFRIA-VIVAS

Prof. Dr. ROSA MARIA FONFRIA-VIVAS

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in JACC: Heart Failure
Verified
Journal Article
Closed access
JNJulio Núñez
Julio Núñez
PLPau Llàcer
Pau Llàcer
VBVicente Bertomeu-Gonzalez
Vicente Bertomeu-Gonzalez
MBMaria José Bosch
Maria José Bosch
PMPilar Merlos
Pilar Merlos
EREva Rumiz
Eva Rumiz

17 October 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
FMFrancisco Miguel Martínez-Arnau
Francisco Miguel Martínez-Arnau
ROSA MARIA FONFRIA-VIVASROSA MARIA FONFRIA-VIVAS
ROSA MARIA FONFRIA-VIVAS
Omar CauliOmar Cauli
Omar Cauli
Objective: Treating sarcopenia remains a challenge, and nutritional interventions present promising approaches. We summarize the effects of leucine supplementation in treating older individuals with sarcopenia associated with aging or to specific disorders, and we focus on the effect of leucine supplementation on various sarcopenia criteria, e.g., muscular strength, lean mass, and physical performance. Methods: A literature search for articles related to this topic was performed on the relevant databases, e.g., the PubMed/Medline, Embase, EBSCO, Cochrane, Lilacs, and Dialnet. The identified articles were reviewed according to Preferred Reporting Items for Systematic reviews and meta-analyses (PRISMA) guidelines. Results: Of the 163 articles we consulted, 23 met our inclusion criteria, analysing the effect of leucine or leucine-enriched protein in the treatment of sarcopenia, and 13 of these studies were based on randomized and placebo-controlled trials (RCTs). In overall terms, the published results show that administration of leucine or leucine-enriched proteins (range 1.2–6 g leucine/day) is well-tolerated and significantly improves sarcopenia in elderly individuals, mainly by improving lean muscle-mass content and in this case most protocols also include vitamin D co-administration. The effect of muscular strength showed mix results, and the effect on physical performance has seldom been studied. For sarcopenia-associated with specific disorders, the most promising effects of leucine supplementation are reported for the rehabilitation of post-stroke patients and in those with liver cirrhosis. Further placebo-controlled trials will be necessary to determine the effects of leucine and to evaluate sarcopenia with the criteria recommended by official Working Groups, thereby limiting the variability of methodological issues for sarcopenia measurement across studies.

27 March 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
FMFrancisco Miguel Martínez-Arnau
Francisco Miguel Martínez-Arnau
ROSA MARIA FONFRIA-VIVASROSA MARIA FONFRIA-VIVAS
ROSA MARIA FONFRIA-VIVAS
CBCristina Buigues
Cristina Buigues
YCYolanda Castillo
Yolanda Castillo
PMPilar Molina
Pilar Molina
Omar CauliOmar Cauli
Omar Cauli
Treating sarcopenia in older individuals remains a challenge, and nutritional interventions present promising approaches in individuals that perform limited physical exercise. We assessed the efficacy of leucine administration to evaluate whether the regular intake of this essential amino acid can improve muscle mass, muscle strength and functional performance and respiratory muscle function in institutionalized older individuals. The study was a placebo-controlled, randomized, double-blind design in fifty participants aged 65 and over (ClinicalTrials.gov identifier NCT03831399). The participants were randomized to a parallel group intervention of 13 weeks’ duration with a daily intake of leucine (6 g/day) or placebo (lactose, 6 g/day). The primary outcome was to study the effect on sarcopenia and respiratory muscle function. The secondary outcomes were changes in the geriatric evaluation scales, such as cognitive function, functional impairment and nutritional assessments. We also evaluated whether leucine administration alters blood analytical parameters and inflammatory markers. Administration of leucine was well-tolerated and significantly improves some criteria of sarcopenia in elderly individuals such as functional performance measured by walking time (p = 0.011), and improved lean mass index. For respiratory muscle function, the leucine-treated group improved significantly (p = 0.026) in maximum static expiratory force compared to the placebo. No significant effects on functional impairment, cognitive function or nutritional assessment, inflammatory cytokines IL-6, TNF-alpha were observed after leucine administration compared to the placebo. The use of l-leucine supplementation can have some beneficial effects on sarcopenia and could be considered for the treatment of sarcopenia in older individuals.

13 July 2023 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
ROSA MARIA FONFRIA-VIVASROSA MARIA FONFRIA-VIVAS
ROSA MARIA FONFRIA-VIVAS
Pilar Pérez-RosPilar Pérez-Ros
Pilar Pérez-Ros
JBJoaquín Barrachina-Igual
Joaquín Barrachina-Igual
APAna Pablos-Monzó
Ana Pablos-Monzó
FMFrancisco M Martínez-Arnau
Francisco M Martínez-Arnau
Background: Health-related quality of life (HRQoL) may be impaired in the presence of sarcopenia. Since a specific quality of life questionnaire became available for sarcopenia (SarQol), cutoffs to screen for this condition have been proposed, prompting the need to assess them in different populations. Due to the lack of consensus on diagnostic criteria, the tool has not yet been analyzed in screening for sarcopenic obesity. Aim: Our aim is to measure the SarQoL’s metric properties and establish a cutoff in QoL assessments that could be used along the diagnostic pathway for sarcopenia and sarcopenic obesity in community-dwelling older women. Methods: This cross-sectional study assessed women aged ≥ 70 years using the SarQol, sarcopenia criteria (EWGSOP2) and sarcopenic obesity criteria (ESPEN/EASO). Cutoffs for the SarQol were defined with a receiver-operating characteristics (ROC) curve, and sensitivity and specificity were analyzed. Results: Of the 95 included women (mean age 76.0 years, standard deviation [SD] 5.7), 7.3% (n = 7) were classified as having sarcopenic obesity, 22.1% (n = 21) as having sarcopenia, and 70.5% (n = 67) as not having sarcopenia. The total SarQol score was higher in women without sarcopenia (66.5 SD 16.2) versus those with sarcopenia (56.6 SD 15.6) and sarcopenic obesity (45.1 SD 7.9). A cutoff of ≤ 60 points is proposed for sarcopenia screening (area under the ROC curve [AUC] 0.67; 95% confidence interval [CI] 0.53–0.80; sensitivity 61.9%; specificity 62%), and ≤ 50 points for sarcopenic obesity (AUC 0.85; 95% CI 0.74–0.95; sensitivity 71.4%; specificity 76.9%). Conclusions: Quality of life is compromised in women with sarcopenia and especially in those with sarcopenic obesity. The SarQol could be useful in screening for these conditions, providing insight into health-related quality of life in older people with sarcopenia.

24 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FMFrancisco Miguel Martínez-Arnau
Francisco Miguel Martínez-Arnau
CBCristina Buigues
Cristina Buigues
ROSA MARIA FONFRIA-VIVASROSA MARIA FONFRIA-VIVAS
ROSA MARIA FONFRIA-VIVAS
Omar CauliOmar Cauli
Omar Cauli
The study of reduced respiratory muscle strengths in relation to the loss of muscular function associated with ageing is of great interest in the study of sarcopenia in older institutionalized individuals. The present study assesses the association between respiratory muscle parameters and skeletal mass content and strength, and analyzes associations with blood cell counts and biochemical parameters related to protein, lipid, glucose and ion profiles. A multicenter cross-sectional study was performed among patients institutionalized in nursing homes. The respiratory muscle function was evaluated by peak expiratory flow, maximal respiratory pressures and spirometry parameters, and skeletal mass function and lean mass content with handgrip strength, walking speed and bioimpedance, respectively. The prevalence of reduced respiratory muscle strength in the sample ranged from 37.9% to 80.7%. Peak expiratory flow significantly (p < 0.05) correlated to handgrip strength and gait speed, as well as maximal inspiratory pressure (p < 0.01). Maximal expiratory pressure significantly (p < 0.01) correlated to handgrip strength. No correlation was obtained with muscle mass in any of parameters related to reduced respiratory muscle strength. The most significant associations within the blood biochemical parameters were observed for some protein and lipid biomarkers e.g., glutamate-oxaloacetate transaminase (GOT), urea, triglycerides and cholesterol. Respiratory function muscle parameters, peak expiratory flow and maximal respiratory pressures were correlated with reduced strength and functional impairment but not with lean mass content. We identified for the first time a relationship between peak expiratory flow (PEF) values and GOT and urea concentrations in blood which deserves future investigations in order to manage these parameters as a possible biomarkers of reduced respiratory muscle strength.

2 December 2024 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
PPPilar Pérez-Ros
Pilar Pérez-Ros
JBJoaquín Barrachina-Igual
Joaquín Barrachina-Igual
APAna Pablos
Ana Pablos
ROSA MARIA FONFRIA-VIVASROSA MARIA FONFRIA-VIVAS
ROSA MARIA FONFRIA-VIVAS
OCOmar Cauli
Omar Cauli
FMFrancisco M. Martínez-Arnau
Francisco M. Martínez-Arnau
Muscle strength is one of the most reliable measures used for the identification of sarcopenia. The European Working Group on Sarcopenia in Older People update (EWGSOP2) proposed the use of grip strength and chair stand tests, while clarifying that isometric torque methods can be used when performing the grip strength test is impossible. This study aims to evaluate the diagnostic accuracy of isometric knee extension strength in screening for sarcopenia. This cross-sectional study included community-dwelling women aged 70 years and over. IKE and sarcopenia criteria (EWGSOP2) were assessed. Skeletal muscle mass was assessed by bioelectrical impedance analysis; muscle mass strength by handgrip; and physical performance by the 5 times sit-to-stand test, the Short Physical Performance Battery, and gait speed. The diagnostic accuracy for each sarcopenia criterion was calculated using sensitivity, specificity, positive and negative predictive value, and the area under the curve (AUC). Cutoff points for sarcopenia from IKE were defined with the ROC curve. The sample comprised 94 women with a mean age of 75.9 years (standard deviation 5.6, range 70–92), of whom 25.5% (n = 24) met criteria for sarcopenia—mainly severe sarcopenia (73.8%, n = 17). Correlations were observed between IKE and each individually analyzed sarcopenia criterion except skeletal muscle mass, with AUC values exceeding 0.70 in all cases. The IKE cutoff showing the highest accuracy for the diagnosis of sarcopenia was 12.5 kg or less (AUC 0.76, 95% confidence interval [CI] 0.64–0.88; sensitivity: 65.2%, 95% CI 45.7–84.7; specificity 77.4%, 95% CI 60.3–94.5; positive predictive value 62.5%, 95 CI% 42.7–82.3; negative predictive value 88.8%, 95% CI 75.9–100). IKE could be a suitable tool for measuring muscular strength in sarcopenia when other strength parameters cannot be assessed or in people with walking difficulties.